A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ?20) (HexAgon-HN)

A clinical trial is testing whether adding an experimental immunotherapy called INBRX-106 to a standard immunotherapy drug improves outcomes for people with advanced head and neck cancer. This matters because recurrent or metastatic head and neck squamous cell carcinoma is difficult to treat, and current first-line options for patients whose tumours express a specific immune marker (PD-L1) have limited effectiveness. The study compares the combination of INBRX-106 and pembrolizumab against pembrolizumab alone. If the combination proves more effective, it could offer a new first-line treatment option for this patient group, potentially extending survival or delaying disease progression. The trial is designed to generate evidence on whether the two immunotherapies work better together than the current standard of care alone.